Provided by Tiger Trade Technology Pte. Ltd.

HBM HOLDINGS-B

14.190
-0.250-1.73%
Volume:8.78M
Turnover:125.24M
Market Cap:12.33B
PE:129
High:14.740
Open:14.440
Low:13.980
Close:14.440
52wk High:17.880
52wk Low:9.460
Shares:869.00M
HK Float Shares:869.00M
Volume Ratio:0.52
T/O Rate:1.01%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.110
ROE:23.97%
ROA:10.88%
PB:3.76
PE(LYR):129.00
PS:8.78

Loading ...

HBM Holdings Added to Hang Seng Composite Index, Enabling Future Stock-Connect Eligibility

Bulletin Express
·
Aug 24

HBM Holdings Surges Nearly 15% as China Approves Clinical Trial Application for Late-Stage Solid Tumor Therapy

Stock News
·
Aug 20

HBM's Cancer Drug Candidate Gets China Approval

MT Newswires Live
·
Aug 18

HBM Holdings Secures NMPA Clearance for HBM7004 IND in Advanced Solid Tumors

Stock News
·
Aug 18

HBM Gets China NMPA Clearance to Start Hbm7004 Trial in Advanced Solid Tumors

Reuters
·
Aug 18

Hbm Holdings - Nmpa Approves Ind Application for Hbm7004 for Advanced Solid Tumors

THOMSON REUTERS
·
Aug 18

HBM Holdings Schedules 27 August 2026 Board Meeting to Approve 1H26 Results

Bulletin Express
·
Aug 17

HBM Holdings Schedules Board Meeting to Review Interim Results

Reuters
·
Aug 17

HBM Holdings (SEHK:2142) Names Metabolic Chief And Partners With Sinopharm, Is It Fully Priced?

Simply Wall St.
·
Aug 09

Hong Kong Stock Movers: HBM Holdings-B Surges Over 7% in Early Trading on First-Half Revenue Growth and Profitability, Following Strategic Partnership with Sinopharm

Stock News
·
Aug 07

HBM Holdings Adds 0.80 Million Shares from Option Exercises, Lifting Total Issued to 900.98 Million

Bulletin Express
·
Aug 06

Harbour BioMed Names Bob Zhang President of Metabolic Disease Franchise

Reuters
·
Aug 06

Harbour Biomed Appoints DR. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies

THOMSON REUTERS
·
Aug 06

Is HBM Holdings (SEHK:2142) Undervalued As Its Sinopharm Biologic Drug Consortium Takes Shape?

Simply Wall St.
·
Jul 29

HBM Holdings-B (02142) Forms Strategic Alliance with China National Pharmaceutical Group to Establish Joint Innovation Body

Stock News
·
Jul 27

Harbour Biomed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium

THOMSON REUTERS
·
Jul 27

Hbm Holdings - Enters Strategic Collaboration with China National Pharmaceutical Group on Biologics R&D

THOMSON REUTERS
·
Jul 27

HBM Holdings Enters Strategic Biologics R&D Collaboration with Sinopharm

Reuters
·
Jul 27

HBM Holdings Expects H1 Profit of Up to $67 Million

MT Newswires Live
·
Jul 24

HBM Holdings Expects HY Revenue $120 Million-$125 Million

Reuters
·
Jul 24